Azelis Group N.V.
AZE
ISIN BE0974400328 / Valor 113722477
Azelis Group N.V.
UMushroom community rating:
About company
Azelis Group N.V. is a leading global distributor of specialty chemicals and food ingredients, serving a wide range of industries including personal care, pharmaceuticals, food and beverage, and industrial chemicals. The company operates through a comprehensive network of suppliers and customers, providing value-added services such as formulation development, technical support, and regulatory guidance. Azelis leverages its extensive market knowledge and technical expertise to deliver innovative solutions tailored to the specific needs of its clients. The company also offers a digital customer portal that facilitates seamless interaction with its offerings, allowing users to access trends, order samples, request quotes, and manage product reorders efficiently. With a strong focus on innovation and customer service, Azelis continues to expand its global footprint and enhance its position as a key player in the specialty chemicals distribution sector.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (01.10.2025):
Azelis Group N.V. reported its financial results for the first half of 2025, showcasing an 11% growth in free cash flow. The company achieved a slight increase in revenue to EUR 2.2 billion, driven by organic growth and acquisitions, despite facing challenges from unfavorable foreign exchange impacts. Net profit declined by 14.6% compared to the previous year, while the leverage ratio rose to 3.1x. Azelis continued its strategic acquisitions and emphasized cost management to navigate ongoing economic uncertainties.
Revenue Growth
Azelis reported a total revenue of EUR 2.2 billion in H1 2025, marking a 0.6% year-on-year increase. This growth was fueled by a 1.2% organic revenue rise and a 2.2% contribution from acquisitions, offset by a 2.7% negative impact from foreign exchange rates.
Profit Margins and Net Profit
The company achieved a gross profit of EUR 515 million with a margin of 23.9%, despite a 68 basis point contraction due to a higher contribution from Industrial Chemicals and less mature business segments. Adjusted EBITA stood at EUR 234 million, with a margin of 10.9%. Net profit decreased by 14.6% to EUR 85 million, primarily due to lower operating profit.
Free Cash Flow and Leverage
Free cash flow surged by 10.8% to EUR 151 million, highlighting the resilient and cash-generative nature of Azelis's business model. However, the leverage ratio increased to 3.1x by June 2025 from 2.7x in the previous June, reflecting slower EBITDA growth and the impact of deferred payments.
Strategic Acquisitions
In the first half of 2025, Azelis completed two acquisitions and announced a third shortly after the period ended. These acquisitions added over EUR 100 million in annual revenue for 2024, strengthening the company's market presence in key regions.
Regional Performance
Revenue in the Life Sciences segment remained stable, while Industrial Chemicals saw a 1.5% increase. The EMEA region reported a 6.7% revenue growth, the Americas experienced a 3.4% decline, and Asia Pacific saw a 4.9% decrease. Gross profit margins varied across regions, reflecting different market dynamics and acquisition impacts.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
3228 M
Market cap (USD)
522,321
Daily traded volume (Shares)
18.85 / 18.53
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
